Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06007638 | A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants | PHASE1 | COMPLETED | 74 | — | — | Aug 23, 2023 | Sep 20, 2025 | Sep 24, 2025 | 1 | Netherlands |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3876602 | EXPERIMENTAL | Single ascending doses of LY3876602 administered intravenously (IV). |
| Placebo | PLACEBO_COMPARATOR | Placebo administered IV. |
| LY3876602 Part B (MAD) | EXPERIMENTAL | Multiple ascending doses of LY3876602 will be administered intravenously (IV). |
| Placebo: Part B (MAD) | PLACEBO_COMPARATOR | Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY3876602 | DRUG | Administered IV. |
| Placebo | DRUG | Administered IV. |
Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation * Have a body mass index with the range of 18 and less than or equal to (≤) 32 kilograms per square meter (kg/m²) * Male or female participants of nonchildbearing potential Exclusion Crit...